Immune Pharmaceuticals
IMNP
IMNP was delisted on the 25th of July, 2018.
11 hedge funds and large institutions have $227K invested in Immune Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 3 closing their positions.
0.22% less ownership
Funds ownership: 1.81% → 1.59% (-0.22%)
15% less funds holding
Funds holding: 13 → 11 (-2)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $27.4K
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock Fund Advisors
San Francisco,
California
|
-$24.2K |
| 2 |
Virtu KCG Holdings
New York
|
-$1.39K |
| 3 |
BlackRock Investment Management
Wilmington,
Delaware
|
-$1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$742 |
IMNP Hedge Fund Activity: Q2 2016 in Review
11 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Immune Pharmaceuticals (IMNP) for Q2 2016, worth a combined $227K — down 19% from $280K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of IMNP and 2 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 0 added.
The largest seller was BlackRock Fund Advisors, cutting an estimated $24.2K.
- 11 institutional investors held Immune Pharmaceuticals (IMNP) as of Q2 2016, down from 13 in Q1 2016.
- Funds reported $227K of Immune Pharmaceuticals stock for Q2 2016, down 19% quarter-over-quarter.
- 2 funds opened new Immune Pharmaceuticals positions in Q2 2016 and 3 closed out, a net change of -1 holder.
- The largest Immune Pharmaceuticals seller in Q2 2016 was BlackRock Fund Advisors, an estimated $24.2K sold.
Based on aggregated 13F filings for Q2 2016.